3D Medicines Patents – Insights & Stats (Updated 2023)

3D Medicines has a total of 43 patents globally, out of which 28 have been granted. Of these 43 patents, more than 74% patents are active. China is where 3D Medicines has filed the maximum number of patents, followed by United States of America and Japan. Parallelly, China seems to be the main focused R&D centre and also is the origin country of 3D Medicines.

3D Medicines Inc. is a biopharmaceutical company in the commercial stage that specializes in creating unique immuno-oncology drugs.

Do read about some of the most popular patents of 3D Medicines which have been covered by us in this article and also you can find 3D Medicines patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over 3D Medicines patent portfolio.

How many patents does 3D Medicines have?

3D Medicines has a total of 43 patents globally. These patents belong to 12 unique patent families. Out of 43 patents, 32 patents are active.

How Many Patents did 3D Medicines File Every Year?

3D Medicines Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or Grant3D Medicines Applications Filed3D Medicines Patents Granted
202316
202216
20214
202016
201912
201852
201716
2016141
20151
201411
20131

How many 3D Medicines patents are Alive/Dead?

Worldwide Patents

3D Medicines Patent Portfolio

How Many Patents did 3D Medicines File in Different Countries?

3D Medicines Worldwide Patent Filing

Countries in which 3D Medicines Filed Patents

CountryPatent
China10
United States Of America3
Japan3
Europe2
Taiwan2
Malaysia1
Germany1
Philippines1
Australia1
Mexico1
Indonesia1
New Zealand1
Brazil1
Russia1
Singapore1
Canada1
Austria1
Macao1
Korea (South)1

Where are Research Centers of 3D Medicines Patents Located?

R&D Centres of 3D Medicines

Best 3D Medicines Patents

CN107849130B is the most popular patent in the 3D Medicines portfolio. It has received 111 citations so far from company like Bj Energy Solutions.

Below is the list of most cited patents of 3D Medicines:

Publication NumberCitation Count
CN107849130B111
WO2017020802A141
WO2017101789A18
CN107011406A4
WO2018090975A12
WO2018090976A12
KR102138447B11
WO2019149219A11
WO2018090974A11

What Percentage of 3D Medicines US Patent Applications Were Granted?

3D Medicines (Excluding its subsidiaries) has filed 3 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 50%.

Below are the key stats of 3D Medicines patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for 3D Medicines?

Law FirmTotal ApplicationsSuccess Rate
Grogan Tuccillo & Vanderleeden Llp2100%
Schwegman Lundberg & Woessner PA10%

List of 3D Medicines patents

3D Medicines PatentsTitle
US11712434B2Compound Having Anti-Cancer Effect, And Preparation Method Therefor And Use Thereof
US11351151B2Compound Having Anticancer Activity And Preparation Method And Application
EP3543228B1Compound Having Anticancer Activity, And Preparation Method And Application Thereof
EP3542796A4Compound Having Anti-Cancer Effect, And Preparation Method Therefor And Use Thereof
CN110167554BA Compound With Anticancer Effect And Its Preparation Method And Application
CN110167917BA Compound With Anticancer Effect And Its Preparation Method And Application
CN108350023BA Compound With Anticancer Effect And Its Preparation Method And Application
CN108137644BA Compound With Antitumor Effect And Its Preparation Method And Application
CN107849130BSingle Domain Antibody Against Programmed Death Ligand (Pd-L1) And Its Derivative Protein
CN106478760BTriad Derivative Tba-X With Anti-Tumor Effect And Its Preparation Method And Application
CN105315321BCompound With Antitumor Effect And Its Preparation Method And Application
CN102675401BPreparation Of Anti-Tumor Medicine Lqc-Y And Application Thereof
CN116514844AThienopyrimidine Derivatives And Application Thereof As General Kras Mutation Inhibitor
WO2023138589A1Five-Membered Heterocyclic Pyrimidine Derivative And Use Thereof As Inhibitor Of Pan-Kras Mutation
JP6999960B2Compound Having Anti-Cancer Action, Method For Producing The Same, And Use Thereof
JP6993721B2Compound Having Anti-Cancer Activity, Method For Producing The Same, And Application Thereof
JP6946289B2Single Domain Antibody Against Programmed Death Ligand (Pdl1) And Its Derivative Protein
KR102138447B1Single Domain Antibodies For Programmed Death Ligand (Pd-L1) And Derived Proteins Thereof
TWI721255BA Compound With Anticancer Effect And Its Preparation Method And Application (1)
TWI703134BA Compound With Anticancer Effect And Its Preparation Method And Application (2)
MX402867BSingle Domain Antibody And Proteins Derived Thereof Against Programmed Death Ligand (Pdl1).
MY195474ASingle Domain Antibody And Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
PH12018500233B1Single Domain Antibody Programmed Death-Ligand (Pd-L1) And Derived Protein Thereof
DE602017065112T2Anti-Cancer Compound And Method Of Manufacture And Use Thereof
CA2994339CSingle Domain Antibody For Programmed Death-Ligand (Pd-L1) And Derived Protein Thereof
IDP000074323BSingle Domain Antibody And Its Derivative Protein For Programmed Death Ligand (Pdll)
MOJ004079CSingle Domain Antibody Against Programmed Death Ligand (Pd-L1) And Its Derivative Protein.
RU2715595C2Single-Domain Antibody And Derivatives Thereof To Ligand-1 Protein Of Programmed Cell Death (Pdli)
NZ739499BSingle Domain Antibody For Programmed Death-Ligand (Pd-L1) And Derived Protein Thereof
AU2016302951B2Single Domain Antibody For Programmed Death-Ligand (Pd-L1) And Derived Protein Thereof
BR112018002130A2Single Domain Antibody And Respective Derivative Proteins Against A Programmed Death Link (Pdl1)
SG11201800815SASingle Domain Antibody For Programmed Death-Ligand (Pd-L1) And Derived Protein Thereof
US9321804B2Synthesis And Use Of Anti-Tumor Drug Lqc-Y
CN107011406AAnti-Tumor Compound As Well As Preparation Method And Application Thereof
WO2019149219A1Use Of Anti-Cd3 Immunotoxin Combined With Anti-Pd-L1 Single Domain Antibody In Treatment Of Cancer
WO2018090974A1Compound Having Anti-Cancer Effect, And Preparation Method Therefor And Use Thereof
WO2018090975A1Compound Having Anticancer Activity, And Preparation Method And Application Thereof
WO2018090979A1Compound Having Anticancer Effect, Preparation Method Therefor, And Applications Thereof
WO2018090976A1Compound Having Anticancer Effect, Preparation Method Therefor, And Applications Thereof
WO2017128981A1Compound Having Anti-Tumour Effect And Preparation Method And Use Thereof
WO2017101789A1Compound Having Anti-Cancer Effect, And Method For Preparation Thereof And Application Thereof
WO2017020802A1Single Domain Antibody For Programmed Death-Ligand (Pd-L1) And Derived Protein Thereof
AT1540404TVerbindung Mit Antikrebswirkung Und Herstellungsverfahren Und Anwendung Davon

What are 3D Medicines key innovation segments?

What Technologies are Covered by 3D Medicines?

The chart below distributes patents filed by 3D Medicines in different countries on the basis of the technology protected in patents. It also represents the markets where 3D Medicines thinks it’s important to protect particular technology inventions.

R&D Focus: How has 3D Medicines search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by 3D Medicines?

Related Articles

Arashi Vision Patents – Insights & Stats (Updated 2024)

Arashi Vision has a total of 1257 patents globally, out of which 751 have been granted. Of these 1257 patents, more than 87% patents are active. China is where Arashi Vision has filed the maximum number of patents, followed by United States of America and Europe (EPO). Parallelly, China seems

Read More »

Terecircuits Patents – Insights & Stats (Updated 2024)

Terecircuits has a total of 43 patents globally, out of which 22 have been granted. Of these 43 patents, more than 37% patents are active. United States of America is where Terecircuits has filed the maximum number of patents, followed by Europe (EPO) and Taiwan. Parallelly, United States of America

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.